To receive a calendar invitation: RSVP here
Missed the event? Visit the Grand Rounds Video Library for on-demand viewing.
“Rapid relapse” triple-negative breast cancer (rrTNBC) is a poor prognosis subset of breast cancer characterized by aggressive disease, chemotherapy resistance, and metastasis or mortality within two years of diagnosis. By pursuing a multi-pronged approach, we have identified key ‘omic features of rrTNBC at diagnosis, social determinants of health associated with rrTNBC, and a key potential driver and therapeutic target for rrTNBC. Collectively, we seek to develop biomarkers and risk models to identify patients at high risk followed by interventions seeking to improve outcomes for these patients.
Daniel Stover, MD
Assistant Professor, Medical Oncology; Member, Translational Therapeutics Program, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Samilia Obeng-Gyasi, MD, MPH
Assistant Professor, Surgical Oncology; Member, Cancer Control Program, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Gina Sizemore, PhD
Assistant Professor, Radiation Oncology; Member, Cancer Biology Program, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute